Dr. Brenner is a neuro-oncologist, medical oncologist and tumor biologist with a focus in drug development for the management of primary brain tumors and breast neoplasms. His interests are in developing novel therapeutics for the treatment of malignancy with a focus on overcoming resistance to conventional therapeutics. This experience includes navigation of regulatory processes including IND enabling studies, authoring study protocols, coordinating multicenter studies, as well as acting as principal investigator of 14 industry and investigator-initiated Phase 1 trials since 2008.

Dr. Brenner earned his bachelor’s degree in biochemistry and went on to earn his doctorate in biological science and tumor biology at The University of Texas M.D. Anderson Cancer Center – Science Park. Following post-doctoral training at the European Institute of Oncology, he completed a medical degree at TTUHSC, medical oncology fellowship at the UT Health San Antonio, followed by ABIM and UCNS certifications. Current responsibilities include Co-Leader of Experimental and Developmental Therapeutics, Neuro-Oncology Program Leader, Breast Program Member, and Clinical Investigator with the Institute for Drug Development.

As a tumor biologist with a focus on translation from bench to clinic, his laboratory performs in vivo evaluation of promising compounds and devices. At present, our laboratory work is geared toward evasive resistance under selective pressure from hypoxia. Once evidence of potential clinical activity is observed, he leads the transition to the clinic. Clinical trial experience spans all phases of drug development, with particular strength in first in human studies.

Andrew Brenner, M.D., Ph.D. is now enrolling patients for the ReSPECT-GBM and ReSPECT-LM clinical trials.